Biosocieties

Papers
(The TQCC of Biosocieties is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-07-01 to 2024-07-01.)
ArticleCitations
Rethinking value construction in biomedicine and healthcare15
The coughing body: etiquettes, techniques, sonographies and spaces10
Life’s continuation: repro-tech, biogenetic affinity, and racial capitalism9
Imagining the public: anticipatory discourses in China’s push for precision medicine8
Core values of genomic citizen science: results from a qualitative interview study8
‘The good economy’: a conceptual and empirical move for investigating how economies and versions of the good are entangled7
The emergence of multimorbidity as a matter of concern: a critical review7
Psychedelic innovations and the crisis of psychopharmacology6
Reprowebs: a conceptual approach to elasticity and change in the global assisted reproduction industry6
Making valuable health: pharmaceuticals, global capital and alternative political economies6
Powering life through MitoTechnologies: exploring the bio-objectification of mitochondria in reproduction6
Concussion killjoys: CTE, violence and the brain’s becoming6
Value-creation in the health data domain: a typology of what health data help us do5
Vegetative value: promissory horizons of therapeutic innovation in the global circulation of ayahuasca5
To wish you well: the biopolitical subjectivities of medical crowdfunders during and after Aotearoa New Zealand’s COVID-19 lockdown5
Mutual visibility and interaction: staff reactions to the ‘healing architecture’ of psychiatric inpatient wards in Denmark5
The Covid-19 caesura and the post-pandemic future5
Fake eggs: from counter-qualification to popular certification in China’s food safety crisis5
Ectogenesis, inequality, and coercion: a reproductive justice-informed analysis of the impact of artificial wombs5
Device activism and material participation in healthcare: retracing forms of engagement in the #WeAreNotWaiting movement for open-source closed-loop systems in type 1 diabetes self-care4
The datafication of pain: trials and tribulations in measuring phantom limb pain4
Beyond secrecy and openness: telling a relational story about children’s best interests in donor-conceived families4
Pharmaceutical innovation and its crisis: drug markets, screening, and the dialectics of value4
N = many me’s: self-surveillance for Precision Public Health4
‘We thank you for your sacrifice’: Clinical vulnerability, shielding and biosociality in the UK’s Covid-19 response4
The FDA’s standard-making process for medical digital health technologies: co-producing technological and organizational innovation4
Beyond the making of altruism: branding and identity in egg donation websites in Spain4
Allostatic load: historical origins, promises and costs of a recent biosocial approach4
Legitimate suffering: a case of belonging and sickle cell trait in Brazil4
Making it happen: data practices and the power of diplomacy among Danish organ transplant coordinators3
Value regimes and pricing in the pharmaceutical industry: financial capital inflation (hepatitis C) versus innovation and production capital savings for malaria medicines3
Genome editing: From bioethics to biopolitics3
The life and death of confidentiality: a historical analysis of the flows of patient information3
Making epistemic goods compatible: knowledge-making practices in a lifestyle intervention RCT on mindfulness and compassion meditation3
The ongoing work of kinship among donor half-siblings in The Netherlands3
Analysing bio-art’s epistemic landscape: from metaphoric to post-metaphoric structure3
“It’s harder for the likes of us”: racially minoritised stem cell donation as ethico-racial imperative3
“The elephant in the room”: social responsibility in the production of sociogenomics research3
Adjusting the analytical aperture: propositions for an integrated approach to the social study of reproductive technologies3
Sexual health as surplus: the marketization of PrEP in Taiwan3
0.078511953353882